Researchers at the Tony Blair Institute for Global Change in the UK suggested that expanding the scope of eligibility to obtain weight loss injections may allow at least 14.7 million Britons to obtain these drugs, which in turn will enhance the national health service.
The institute called in the statement, which was published in May and the British Daily Mail newspaper wrote to reduce the standards of eligibility to obtain drugs significantly, to make them available to people with weight gain, but they are not obese yet.
As part of their research, they also suggested providing weight loss medications without a prescription, without the need to visit a general doctor first, and provide weight management services through the application of British National Health Service. The institute argues that such steps would enhance the health and wealth of the nation, and help in addressing inequality.
Obesity is now one of the largest causes of UK health disorder
The National Health Services Authority distributes these medications to about 50,000 people annually in specialized weight loss clinics, although 4 million people have a body mass index higher than 35 qualified to get them.
The BMI, which is more than 30, is classified as obesity, and the body mass index is categorized as excessive obesity. It is believed that half a million people are especially receiving treatment for about 200 pounds per month (about 268 dollars).
The institute’s report calls for “a faster and broader approach to the medicine”, and they suggest making the BMI to obtain injections is only 27 (which means that the patient suffers from weight gain).
Your fellowship supports productivity
Weight loss injections have shown a noticeable increase in workforce productivity, as users usually have better physical fitness and take less satisfactory leave. In experiments, weight loss medications helped people lose up to five body weight, which may reduce the risk of diabetes, heart disease and cancer.
Ministers are studying Sabla to make weight loss medications more easily, and Treasury officials are talking about their economic benefits.
The Public Health Research Institute says that the current approach to the National Health Services Authority “is unlikely to slow down, not to mention the reflection of the high rates of obesity over the next 12 years”, and that the need to refer a public doctor hinders the possibility of offering it on a broader scale due to its great consumption of resources and its high cost.
The economic modeling conducted by the institute shows that reducing the qualified body mass index is expected to achieve a balance between cost and interest by 2035, and net gains on an annual basis after that, with cumulative financial benefits estimated at 52 billion pounds (approximately 70 billion) by 2050.
Growth
“If the government is looking to improve health and pay economic growth, the treatment of obesity – as a part of a broader protective agenda – should be a major priority,” said Dr. Charlotte Rivsum, the institute’s director of health policy.
A study presented at the European Obesity Conference earlier this month found that the medication of Simiglotide – which is sold under the trade name Ozmbeak as a treatment for diabetes or Wigofi to lose weight – is enhanced by annual productivity, equivalent to 1127 pounds per person (approximately 1500 dollars).
The drug helped each patient avoid 5 days satisfactory annually on average, and enabled people to do an additional 12 days of unpaid productive activities, such as volunteering or childcare, providing state resources.
In total, this will be equivalent to 4.5 billion pounds (approximately 6 billion dollars) annually in British economic productivity if 4 million people are qualified to obtain the drug from the National Health Services Authority to obtain it.